LS CancerDiag Ltd is committed to reducing cancer mortality rates with an efficient, simple diagnostic method.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Helsinki
State: Southern Finland
Zip:
Country: Finland
LS CancerDiag Ltd is committed to reducing cancer mortality rates with an efficient, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2016 | Seed Round | 1 | - |
StartUp Health StartUp Health |
4/2016 | Seed Round | 1 | - |
StartUp Health StartUp Health |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|